Drugs / DP-b99
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT02025049 | Dec 2013 → May 2015 | pancreatitis | D-Pharm Ltd. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00190047 | Feb 2005 → Oct 2006 | brain ischemia, ischemic stroke | D-Pharm Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00893867 | Dec 2009 → Apr 2012 | ischemic stroke | D-Pharm Ltd. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DP-b99 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00190047 ↗ |
| Modality | Other / unclassified | “metal ion trapping agent DP-b99” NCT00893867 ↗ |
| Route | Intravenous | “2-hour intra-venous infusion of DP-b99 or placebo.” NCT00190047 ↗ |